1. Home
  2. PPL vs INSM Comparison

PPL vs INSM Comparison

Compare PPL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPL Corporation

PPL

PPL Corporation

HOLD

Current Price

$38.80

Market Cap

29.9B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$143.43

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPL
INSM
Founded
1920
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9B
30.1B
IPO Year
2007
2000

Fundamental Metrics

Financial Performance
Metric
PPL
INSM
Price
$38.80
$143.43
Analyst Decision
Buy
Strong Buy
Analyst Count
13
24
Target Price
$40.69
$201.17
AVG Volume (30 Days)
5.8M
2.4M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
2.92%
N/A
EPS Growth
32.50
N/A
EPS
1.59
N/A
Revenue
$9,042,000,000.00
N/A
Revenue This Year
$7.23
$182.31
Revenue Next Year
$5.85
$65.19
P/E Ratio
$24.57
N/A
Revenue Growth
6.85
N/A
52 Week Low
$33.17
$63.81
52 Week High
$40.11
$212.75

Technical Indicators

Market Signals
Indicator
PPL
INSM
Relative Strength Index (RSI) 52.38 41.41
Support Level $35.21 $142.99
Resistance Level $39.04 $149.08
Average True Range (ATR) 0.59 5.62
MACD -0.02 -1.75
Stochastic Oscillator 45.89 11.10

Price Performance

Historical Comparison
PPL
INSM

About PPL PPL Corporation

PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: